Splenectomy in cytoreductive surgery for advanced ovarian cancer

被引：10
作者：
Bilgin T. [1 ]
Özerkan K. [1 ]
Ozan H. [1 ]
机构：
[1] Dept. of Obstetrics and Gynecology, Faculty of Medicine, Uludaǧ University
来源：
Archives of Gynecology and Obstetrics | 2005年 / 271卷 / 4期
关键词：
Cytoreduction; Ovarian cancer; Splenectomy; Surgery;
D O I：
10.1007/s00404-004-0612-3
中图分类号：
学科分类号：
摘要：
Methods: To evaluate the series of advanced ovarian cancer patients who underwent splenectomy as part of their surgery, a retrospective file review of 258 ovarian cancer cases were examined. Results: There were 13 cases that underwent splenectomy. These patients constitute 5% of all and 8.8% of the advanced ovarian cancer patients. Seven cases had splenectomy as part of their initial cytoreductive surgery while 6 had surgery for recurrent disease. Splenectomy was performed to resect hilar and/or capsular involvement in 9 (69%) cases, while in 3 cases (23%) splenic injury during adjacent tumoral resection required splenectomy. One patient had splenectomy for infarcts and died after the surgery with systemic complications nonrelated to the surgery. No other serious morbidity was detected. Median survival of the patients was 34 months (1-120 months) from the initial diagnosis. Median survival was 18 months (1-78 months) after the splenectomy. Three patients were still alive with no evidence of disease 2, 5 and 6.5 years after the splenectomy. Conclusion: Splenectomy is a feasible and safe procedure. However, it should be reserved for patients in whom optimal cytoreductive results could be achieved. © Springer-Verlag 2004.
引用
收藏
页码：329 / 331
页数：2
相关论文
共 8 条
  • [1] Chen L., Leuchter R.S., Lagasse L.D., Karlan B.Y., Splenectomy and surgical cytoreduction for ovarian cancer, Gynecol Oncol, 77, pp. 362-368, (2000)
  • [2] Gemignani M.L., Chi D.S., Gurin C.C., Curtin J.P., Barakat R.R., Splenectomy in recurrent epithelial ovarian cancer, Gynecol Oncol, 72, pp. 407-410, (1999)
  • [3] Gershenson D.M., Primary cytoreduction for advanced epithelial ovarian cancer, Obstet Gynecol Clin North Am, 21, pp. 121-140, (1994)
  • [4] Menczer J., Schejter E., Geva D., Ginath S., Zakut H., Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival, Eur J Gynaecol Oncol, 19, pp. 82-84, (1998)
  • [5] Morris M., Gershenson D.M., Burke T.W., Wharton J.T., Copeland L.J., Rutledge F.N., Splenectomy in gynecologic oncology: Indications, complications, and technique, Gynecol Oncol, 43, pp. 118-122, (1991)
  • [6] Nelson B.E., Rose P.G., Reale F.R., Isolated parenchymal splenic metastasis in epithelial ovarian cancer, Gynecol Oncol, 50, pp. 124-127, (1993)
  • [7] Randi M.L., Fabris F., Dona S., Girolami A., Evaluation of platelet function in postsplenectomy thrombocytosis, Folia Haematol Int Mag Klin Morphol Blutforsch, 114, pp. 252-256, (1987)
  • [8] Rose P.G., Piver M.S., Tsukada Y., Lau T., Metastatic patterns in histologic variants of ovarian cancer. An autopsy study, Cancer, 64, pp. 1508-1513, (1989)
1